Édith Borcoman

2.5k total citations · 1 hit paper
50 papers, 1.3k citations indexed

About

Édith Borcoman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Édith Borcoman has authored 50 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 11 papers in Immunology. Recurrent topics in Édith Borcoman's work include Cancer Immunotherapy and Biomarkers (22 papers), Head and Neck Cancer Studies (10 papers) and Immunotherapy and Immune Responses (8 papers). Édith Borcoman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Head and Neck Cancer Studies (10 papers) and Immunotherapy and Immune Responses (8 papers). Édith Borcoman collaborates with scholars based in France, Spain and United States. Édith Borcoman's co-authors include Christophe Le Tourneau, Sanjay Goel, Maxime Frélaut, Vincent Servois, Stéphane Champiat, Philippe L. Bédard, Yada Kanjanapan, Shotaro Kato, Razelle Kurzrock and Georgina V. Long and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Édith Borcoman

45 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel patterns of response under immunotherapy

2019 354 citations Édith Borcoman, Yada Kanjanapan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Édith Borcoman France	17	948	419	281	239	170	50	1.3k
Sheena Bhalla United States	8	775 0.8×	327 0.8×	372 1.3×	301 1.3×	144 0.8×	26	1.3k
Louise C. Connell United States	8	1.2k 1.3×	347 0.8×	376 1.3×	242 1.0×	107 0.6×	31	1.6k
Jashodeep Datta United States	22	801 0.8×	432 1.0×	407 1.4×	351 1.5×	199 1.2×	83	1.4k
Maria A. González-Carmona Germany	20	589 0.6×	294 0.7×	271 1.0×	249 1.0×	173 1.0×	79	1.3k
Miso Kim South Korea	25	1.2k 1.3×	710 1.7×	276 1.0×	292 1.2×	208 1.2×	87	1.7k
Daniel L. Suzman United States	19	1.3k 1.4×	812 1.9×	318 1.1×	352 1.5×	250 1.5×	59	2.0k
Joseph McLaughlin United States	10	1.1k 1.2×	575 1.4×	448 1.6×	176 0.7×	204 1.2×	14	1.4k
Olivier Dubreuil France	15	932 1.0×	498 1.2×	259 0.9×	310 1.3×	382 2.2×	56	1.6k
Diégo Tosi France	20	621 0.7×	386 0.9×	201 0.7×	365 1.5×	146 0.9×	73	1.4k
Shaad E. Abdullah United States	16	573 0.6×	271 0.6×	211 0.8×	168 0.7×	215 1.3×	63	911

Countries citing papers authored by Édith Borcoman

Since Specialization

Citations

This map shows the geographic impact of Édith Borcoman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Édith Borcoman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Édith Borcoman more than expected).

Fields of papers citing papers by Édith Borcoman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Édith Borcoman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Édith Borcoman. The network helps show where Édith Borcoman may publish in the future.

Co-authorship network of co-authors of Édith Borcoman

This figure shows the co-authorship network connecting the top 25 collaborators of Édith Borcoman. A scholar is included among the top collaborators of Édith Borcoman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Édith Borcoman. Édith Borcoman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Canale, Fernando P., Sabrina Bossio, Jimena Tosello, et al.. (2025). CD8 ⁺ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance. OncoImmunology. 14(1). 2502354–2502354. 3 indexed citations

Frenel, Jean‐Sébastien, Claire Cropet, Édith Borcoman, et al.. (2025). Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study. Journal for ImmunoTherapy of Cancer. 13(1). e010708–e010708. 1 indexed citations

Frenel, Jean‐Sébastien, et al.. (2025). Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study. The Breast. 83. 104549–104549. 1 indexed citations

Brenet, Olivier, et al.. (2025). Development of a Prognostic Score in Patients With Advanced Breast Cancer Treated for Meningeal Carcinomatosis. The Breast Journal. 2025(1). 5438600–5438600.

Joseph, Adrien, Stéphanie Pons, Djamel Mokart, et al.. (2024). Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study. SHILAP Revista de lepidopterología. 5(1). 64–69.

Tourneau, Christophe Le, Massimo Ghiani, M.C. Cau, et al.. (2023). First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE. Cancer Reports. 6(5). e1804–e1804. 4 indexed citations

Bossio, Sabrina, Jimena Tosello, Fernando P. Canale, et al.. (2023). CD39 ⁺ conventional CD4 ⁺ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade. OncoImmunology. 12(1). 2246319–2246319. 10 indexed citations

Borcoman, Édith, Catherine Genestie, Patricia Pautier, et al.. (2023). Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer. International Journal of Molecular Sciences. 24(14). 11570–11570. 3 indexed citations

Hervieu, Alice, J. Guigay, Édith Borcoman, et al.. (2022). 478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study. Annals of Oncology. 33. S758–S759. 4 indexed citations

10.

Loirat, Delphine, Édith Borcoman, Audrey Bellesœur, et al.. (2022). Abstract P2-13-27: Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study. Cancer Research. 82(4_Supplement). P2–13.

11.

Saleh, Khalil, Anne Aupérin, Nicolas Martin, et al.. (2021). Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. European Journal of Cancer. 157. 190–197. 10 indexed citations

12.

Hoffmann, Caroline, Valentin Calugaru, Édith Borcoman, et al.. (2021). Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. European Journal of Cancer. 146. 135–144. 45 indexed citations

13.

Paolettí, Xavier, Vincent Servois, Patricia Tresca, et al.. (2021). Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy. Drugs in R&D. 21(4). 399–406. 15 indexed citations

14.

Borcoman, Édith, et al.. (2021). HDAC Inhibition to Prime Immune Checkpoint Inhibitors. Cancers. 14(1). 66–66. 47 indexed citations

15.

Tourneau, Christophe Le, Yungan Tao, Carlos Gomez‐Roca, et al.. (2020). Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 26(24). 6429–6436. 22 indexed citations

16.

Even, Caroline, Matthieu Texier, Christophe Le Tourneau, et al.. (2020). 970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 31. S682–S683. 2 indexed citations

17.

Tourneau, Christophe Le, Jean‐Pierre Delord, Nuria Kotecki, et al.. (2020). A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours. British Journal of Cancer. 123(10). 1481–1489. 5 indexed citations

18.

Frélaut, Maxime, et al.. (2020). Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs. 34(4). 463–476. 67 indexed citations

19.

Borcoman, Édith, Yada Kanjanapan, Stéphane Champiat, et al.. (2019). Novel patterns of response under immunotherapy. Annals of Oncology. 30(3). 385–396. 354 indexed citations breakdown →

20.

Paolettí, Xavier, Vincent Servois, Elvire Pons‐Tostivint, et al.. (2019). Dissociated responses in patients with metastatic solid tumours treated with immunotherapy. Annals of Oncology. 30. v521–v521. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact